Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1995 1
2000 1
2007 1
2008 2
2014 1
2017 2
2018 1
2019 1
2020 1
2021 1
2022 2
2023 5
2024 3
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data.
Piselli P, Tavelli A, Cimaglia C, Muccini C, Bandera A, Marchetti GC, Torti C, Mazzotta V, Pipitò L, Caioli A, Girardi E, Antinori A, Serraino D, d'Arminio Monforte A, Cingolani A; Icona Foundation Study Group. Piselli P, et al. Int J Cancer. 2025 Sep 15;157(6):1142-1153. doi: 10.1002/ijc.35493. Epub 2025 May 29. Int J Cancer. 2025. PMID: 40437996 Free PMC article.
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona).
Mazzotta V, Nozza S, Lanini S, Moschese D, Tavelli A, Rossotti R, Fusco FM, Biasioli L, Matusali G, Raccagni AR, Mileto D, Maci C, Lapadula G, Di Biagio A, Pipitò L, Tamburrini E, Monforte AD, Castagna A, Antinori A; mpox-Icona study group. Mazzotta V, et al. EBioMedicine. 2024 Sep;107:105289. doi: 10.1016/j.ebiom.2024.105289. Epub 2024 Aug 22. EBioMedicine. 2024. PMID: 39178746 Free PMC article.
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort.
Gagliardini R, De Benedittis S, Tavelli A, Lapadula G, Mazzotta V, Bruzzesi E, Cervo A, Carrozzo G, Saracino A, Rusconi S, Marchetti G, Ceccherini-Silberstein F, Antinori A, d'Arminio Monforte A, Muccini C; Icona Foundation Study Group. Gagliardini R, et al. J Antimicrob Chemother. 2025 Aug 1;80(8):2169-2178. doi: 10.1093/jac/dkaf184. J Antimicrob Chemother. 2025. PMID: 40570134 Free PMC article.
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation.
Mussini C, Giacomelli A, Quiros-Roldan E, Mazzotta V, Di Biagio A, De Vito A, Costantini A, D'Ettorre G, Giacometti A, Vergori A, Tavelli A, Malagnino V, Castagna A, Chester J, Antinori A, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Cohort Study for the Icona Foundation Study Group. Mussini C, et al. EClinicalMedicine. 2025 Jul 24;86:103368. doi: 10.1016/j.eclinm.2025.103368. eCollection 2025 Aug. EClinicalMedicine. 2025. PMID: 40740293 Free PMC article.
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort.
De Vito A, Tavelli A, Cozzi-Lepri A, Giacomelli A, Rossotti R, Ponta G, Bobbio N, Ianniello A, Cingolani A, Madeddu G, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group. De Vito A, et al. HIV Med. 2025 Jun;26(6):970-977. doi: 10.1111/hiv.70037. Epub 2025 Apr 28. HIV Med. 2025. PMID: 40296167 Free PMC article.
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort.
Vergori A, Cozzi-Lepri A, Lo Caputo S, Tavelli A, Mazzotta V, Schiaroli E, Orofino G, Mussini C, Nozza S, Cingolani A, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group. Vergori A, et al. J Antimicrob Chemother. 2025 Sep 23:dkaf345. doi: 10.1093/jac/dkaf345. Online ahead of print. J Antimicrob Chemother. 2025. PMID: 40985146 Free article.
Family caregiving for persons with heart failure at the intersection of heart failure and palliative care: a state-of-the-science review.
Nicholas Dionne-Odom J, Hooker SA, Bekelman D, Ejem D, McGhan G, Kitko L, Strömberg A, Wells R, Astin M, Metin ZG, Mancarella G, Pamboukian SV, Evangelista L, Buck HG, Bakitas MA; IMPACT-HF National Workgroup. Nicholas Dionne-Odom J, et al. Among authors: mancarella g. Heart Fail Rev. 2017 Sep;22(5):543-557. doi: 10.1007/s10741-017-9597-4. Heart Fail Rev. 2017. PMID: 28160116 Free PMC article. Review.
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
Capone S, Fusco FM, Milleri S, Borrè S, Carbonara S, Lo Caputo S, Leone S, Gori G, Maggi P, Cascio A, Lichtner M, Cauda R, Dal Zoppo S, Cossu MV, Gori A, Roda S, Confalonieri P, Bonora S, Missale G, Codeluppi M, Mezzaroma I, Capici S, Pontali E, Libanore M, Diani A, Lanini S, Battella S, Contino AM, Piano Mortari E, Genova F, Parente G, Dragonetti R, Colloca S, Visani L, Iannacone C, Carsetti R, Folgori A, Camerini R; COVITAR study group. Capone S, et al. Cell Rep Med. 2023 Jun 20;4(6):101084. doi: 10.1016/j.xcrm.2023.101084. Epub 2023 May 29. Cell Rep Med. 2023. PMID: 37315558 Free PMC article. Clinical Trial.
Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH.
Tortellini E, Zingaropoli MA, Mancarella G, Marocco R, Carraro A, Jamhour M, Barbato C, Guardiani M, Dominelli F, Pasculli P, Napoli A, Gaeta A, Mengoni F, Zuccalà P, Belvisi V, Kertusha B, Parente A, Del Borgo C, Vullo V, Ciardi MR, Mastroianni CM, Lichtner M, Latina Covid-Group. Tortellini E, et al. Among authors: mancarella g. Int J Mol Sci. 2022 Nov 30;23(23):14988. doi: 10.3390/ijms232314988. Int J Mol Sci. 2022. PMID: 36499317 Free PMC article.
28 results